Results 71 to 80 of about 13,103,023 (178)
Advances in new antivirals for chronic hepatitis B
. Chronic hepatitis B virus (HBV) infection remains a global health burden. Timely and effective antiviral therapy is beneficial for patients with HBV infection. With existing antiviral drugs, including nucleos(t)ide analogs and interferon-alfa, patients
Yanhua Tang +5 more
doaj +1 more source
Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B
Long-term treatment with nucleos(t)ide analogs (NAs) is the current first line therapy for patients with chronic hepatitis B (CHB), recommended by most of the current guidelines.
Tout I. +3 more
core +1 more source
Chronic Hepatitis B in the United States: Current Landscape, Unmet Needs and Future Directions
ABSTRACT Chronic hepatitis B (CHB) infection represents a major public health challenge in the US, with substantial unmet needs related to timely diagnosis, treatment, monitoring and disease management. This narrative review explores the CHB landscape in the US, including gaps in patient care, the evolving therapeutic landscape, the clinical utility of
Chari Cohen +3 more
wiley +1 more source
Abstract Clinical pharmacokinetic drug–drug interaction (PK‐DDI) studies are frequently required in drug development when metabolizing enzymes and transporters determine pharmacokinetics. Drugs can be victims, perpetrators, or victims and perpetrators, of PK‐DDIs, so the clinical consequences of these interactions, particularly the risks of severe ...
Thomas M. Polasek, John O. Miners
wiley +1 more source
High serum growth differentiation factor 15 is a risk factor for the occurrence of hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs [PDF]
Sometani E., Hikita H., Murai K., et al. High serum growth differentiation factor 15 is a risk factor for the occurrence of hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs.
Umezawa, Akihiro +22 more
core +1 more source
Chronic Hepatitis B Patients Referred for Liver Transplantation After Nucleos(t)ide Analog Cessation
ABSTRACT Nucleos(t)ide analogs (NAs) provide prolonged viral suppression with favourable clinical outcomes in chronic hepatitis B (CHB) patients. Characterisation of adverse hepatic events after NA cessation leading to liver transplantation (LT) is vital to the improvement of patient management and safety considerations.
Grishma Hirode +10 more
openaire +2 more sources
This review summarizes current therapeutic and prophylactic strategies for global viral diseases, including vaccines, PrEP, direct‐acting antivirals, and emerging modalities such as CRISPR and siRNA. It highlights their clinical impact, ongoing challenges, and future priorities toward broader protection, improved delivery, and more effective antiviral ...
Sawar Khan +12 more
wiley +1 more source
The HLA‐A*11:01 allele is associated with persistent viraemia and advanced liver fibrosis in HDV infection. HLA‐A*11:01 carriers exhibit a reduced T‐cell repertoire, suggesting a narrower T‐cell response to the infection. ABSTRACT Background Hepatitis delta virus (HDV) infection causes the most severe form of viral hepatitis, with highly heterogeneous ...
Maria Francesca Cortese +11 more
wiley +1 more source
Demographic characteristics and clinical features of 67 patients with chronic HBV infection following propensity score matching between the 144-week period before the nucleos(t)ide analog switching and at the time of the switching.
Shunsuke Yamada (1291752) +11 more
core +1 more source
We carried out proteomic analysis of serum extracellular vesicles to identify biomarkers predictive of hepatocellular carcinoma (HCC) development in patients with chronic hepatitis B receiving nucleos(t)ide analog therapy. Candidate proteins identified through proteomic analysis were subsequently quantified in serum by ELISA.
Emi Sometani +21 more
wiley +1 more source

